| Literature DB >> 33214920 |
Alexandra Curtis1, Jeong Su Lee1, Georgios Kaltsakas1,2, Vivian Auyeung2, Simon Shaw1, Nicholas Hart1,2, Joerg Steier1,2.
Abstract
BACKGROUND: Post-polio syndrome is characterised by symptoms of fatigue, pain and new-onset neuromuscular weakness, and emerges decades after the initial poliovirus infection. We sought to evaluate the only post-polio syndrome specific self-management programme in the United Kingdom.Entities:
Keywords: Rehabilitation; fatigue; post-polio syndrome (PPS); quality of life (QoL)
Year: 2020 PMID: 33214920 PMCID: PMC7642628 DOI: 10.21037/jtd-cus-2020-009
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Description of the outcome measures used to evaluate PPS symptoms. All are scores except, the 10-meter walk test was measured in meters per second, the 2-minute walk test was measured in meters and 30sCST measured in repetitions
| Outcome measure | Description and scoring | Date commenced |
|---|---|---|
| Physical effects related to PPS | ||
| IPPS | Likert scale, severity of PPS specific symptoms. Twelve items clustered into 4 constructs: pain 0–30 points, atrophy 0–15 points, bulbar function 0–10 points, temperature control 0–5 points | Sep 2006 |
| MAF | Fatigue rated over the last week, 16 items, 0–50 points | Aug 2016 |
| Understanding of PPS | ||
| PPS Knowledge test† | PPS knowledge 0–22 points | Oct 2003 |
| Well-being | ||
| QoL visual analogue scale | Quality of life scale with no anchors 0–100 points | Jan 2003 |
| COPM | Rating performance (COPM-p) and satisfaction (COPM-s) with activities self-identified as important, both 0–50 points | May 2005 |
| PHQ-9 | Depression: normal 0–4, mild 5–9, moderate 10–14, moderately severe 15–19, severe 20–27 points | Sep 2015 |
| GAD-7 | Anxiety: none 0–5, mild 6–10, severe 16–21 points | Sep 2015 |
| Physical function | ||
| 10-meter walk test‡ | Walk speed in meters per second (m/s) | Jan 2003 |
| 2-minute walk test‡ | Distance in meters (m) | Aug 2010 |
| 30sCST‡ (Modified) | Number of repetitions over 30 seconds, (allowing arm use and from a comfortable height) | Nov 2016 |
†, outcome measures were retested at 6 months, except the PPS knowledge test which was retested on the final day of the PPS course; ‡, outcomes measured by clinicians, all others are self-reported. PPS, post-polio syndrome; IPPS, The Index of Post-polio Sequelae; MAF, Multidimensional Assessment of Fatigue; QoL, quality of life; COPM, Canadian Occupational Performance Measure; PHQ-9, Patient Health Questionnaire; GAD-7, General Anxiety Disorder; 30sCST, 30-second Chair Stand test.
Demographic data of patients attending the PPS self-management courses
| Variables | Value |
|---|---|
| Gender (n=214), n (%) | |
| Male | 79 (36.9) |
| Female | 135 (63.1) |
| Age (n=214), mean (SD) [range] (years) | 61.3 (8.4) [34–85] |
| <65 years old, n (%) | 134 (62.6) |
| ≥65 years old, n (%) | 80 (37.4) |
| Decade of contracting acute polio (n=195), n (%) | |
| 1930–1939 | 4 (2.1) |
| 1940–1949 | 51 (26.2) |
| 1950–1959 | 112 (57.4) |
| 1960–1969 | 19 (9.7) |
| 1970–1979 | 5 (2.6) |
| 1980–1989 | 4 (2.1) |
| Geographical area where acute polio was contracted (n=197), n (%) | |
| UK | 163 (82.7) |
| Africa | 11 (5.6) |
| Asia | 8 (4.1) |
| Middle East | 7 (3.6) |
| Europe | 4 (2.0) |
| South America | 3 (1.5) |
| Canada | 1 (0.5) |
| Area of the body with residual weakness following acute polio (n=198), n (%) | |
| Unilateral LL | 80 (40.4) |
| Bilateral LL | 51 (25.8) |
| UL and LL | 39 (19.7) |
| Spine/spine and limbs | 21 (10.6) |
| UL unilateral | 4 (2.0) |
| UL bilateral | 2 (1.0) |
| None | 1 (0.5) |
PPS, post-polio syndrome; SD, standard deviation; UK, United Kingdom; LL, lower limb; UL, upper limb.
Measures of PPS symptoms, physical function, well-being and PPS knowledge at baseline and 6-month follow-up
| Outcome measure | Baseline | 6-month follow-up | P value |
|---|---|---|---|
| Physical effects related to PPS | |||
| IPPS (n=142) | |||
| Pain | 15.0 (6.1) | 13.1 (6.7) | 0.001 |
| Atrophy | 10.0 (8.0–12.0) | 9.0 (7.0–11.0) | 0.002 |
| Bulbar | 3.0 (1.0–5.0) | 2.0 (0–4.0) | 0.003 |
| Temperature | 3.0 (2.0–4.0) | 4.0 (2.0–4.0) | 0.900 |
| MAF (n=45) | 37.6 (7.1) | 34.2 (9.3) | 0.005 |
| Well-being | |||
| QoL (n=178) | 60 [50–70] | 60 [55–70] | 0.200 |
| COPM (n=153) | |||
| Performance | 6.6 (4.8–7.6) | 6.6 (5.0–7.0) | 0.170 |
| Satisfaction | 6.0 (4.1–7.2) | 6.6 (5.0–7.5) | 0.001 |
| PHQ-9 (n=60) | 2.0 (0.3–10.8) | 2.0 (0.3–6.8) | 0.450 |
| GAD-7 (n=60) | 2.0 (0–7.0) | 1.0 (0–3.0) | 0.460 |
| Physical function | |||
| 10-m walk speed (m/s) (n=159) | 0.77 (0.59–1.00) | 0.83 (0.67–1.10) | 0.003 |
| 2-minute walk test (m) (n=81) | 76.9 (31.7) | 82.0 (38.4) | 0.029 |
| 30sCST (repetitions) (n=33) | 6.7 (3.0) | 7.1 (3.1) | 0.221 |
| Understanding of PPS | |||
| Knowledge test (n=138) | 14.0 (11.0–16.0) | 17.0 (16.0–19.0) | 0.001 |
IPPS, The Index of Post-polio Sequelae; MAF, Multidimensional Assessment of Fatigue; QoL, quality of life; COPM, Canadian Occupational Performance Measure; PHQ-9, Patient Health Questionnaire; GAD-7, General Anxiety Disorder; 30sCST, 30-second Chair Stand test.
Comparison of gender proportion between the participants whose outcomes measures were included in the study and the participants whose outcomes were missing
| Outcome measure | Participants with included outcome measures | Participants with missing data | P | |||
|---|---|---|---|---|---|---|
| Number | Female/male | Number | Female/male | |||
| IPPS | 142 | 90/52 | 26 | 18/8 | 0.660 | |
| MAF | 45 | 32/13 | 5 | 4/1 | >0.999 | |
| QoL | 178 | 114/64 | 35 | 20/15 | 0.450 | |
| COPM | 153 | 98/55 | 61 | 37/24 | 0.640 | |
| PHQ-9 | 60 | 39/21 | 8 | 5/3 | >0.999 | |
| GAD-7 | 60 | 39/21 | 8 | 5/3 | >0.999 | |
| 10-m walk test | 159 | 102/57 | 55 | 33/22 | 0.628 | |
| 2-minute walk test | 81 | 51/30 | 41 | 24/17 | 0.695 | |
| 30sCST | 33 | 24/9 | 17 | 10/7 | 0.353 | |
| Knowledge test | 138 | 82/56 | 76 | 53/23 | 0.849 | |
IPPS, The Index of Post-polio Sequelae; MAF, Multidimensional Assessment of Fatigue; QoL, quality of life; COPM, Canadian Occupational Performance Measure; PHQ-9, Patient Health Questionnaire; GAD-7, General Anxiety Disorder; 30sCST, 30-second Chair Stand test.
Comparison of age difference between the participants whose outcome measures were included in the study and the participants whose outcomes were missing
| Outcome measure | Participants with included outcome measures | Participants with missing data | Percentage of missing data | P | |||
|---|---|---|---|---|---|---|---|
| Number | Age, mean (SD) | Number | Age, mean (SD) | ||||
| IPPS | 142 | 63.4 (7.8) | 26† | 58.4 (10.4) | 15% | – | |
| MAF | 45 | 65.1 (9.6) | 5† | 49.8 (10.5) | 10% | – | |
| QoL | 178 | 61.8 (8.3) | 35 | 59.3 (9.0) | – | 0.115 | |
| COPM | 153 | 62.6 (8.2) | 61 | 58.2 (8.4) | – | 0.010* | |
| PHQ-9 | 60 | 64.8 (9.4) | 8† | 54.9 (11.0) | 12% | – | |
| GAD-7 | 60 | 64.8 (9.4) | 8† | 54.9 (11.0) | 12% | – | |
| 10m walk speed | 159 | 61.7 (8.0) | 55 | 60.1 (9.6) | – | 0.234 | |
| 2-minute walk test | 81 | 64.4 (7.6) | 41 | 61.6 (10.0) | – | 0.084 | |
| 30sCST | 33 | 64.1 (10.0) | 17† | 61.3 (12.8) | 34% | – | |
| Knowledge test | 138 | 62.0 (8.5) | 76 | 60.2 (8.2) | – | 0.135 | |
†, outcome measures with less than 30 missing data sets; *, P value ≤0.05. IPPS, The Index of Post-polio Sequelae; MAF, Multidimensional Assessment of Fatigue; QoL, quality of life; COPM, Canadian Occupational Performance Measure; PHQ-9, Patient Health Questionnaire; GAD-7, General Anxiety Disorder; 30sCST, 30-second Chair Stand test.